Anthem Biosciences Limited has scheduled its 20th Annual General Meeting (AGM) for Wednesday, July 22, 2026, at 3:30 p.m. IST through Video Conferencing (VC) or Other Audio Visual Means (OAVM). The meeting seeks shareholder approval for a final dividend of ₹2 per equity share for the financial year ended March 31, 2026. The record date for determining shareholder eligibility is Friday, June 26, 2026, and the dividend is scheduled to be paid on or before Friday, August 21, 2026, subject to approval at the AGM.

The Board of Directors recommended the dividend at a meeting held on May 19, 2026. The company has appointed KFin Technologies Limited as the Registrar and Share Transfer Agent to facilitate the virtual meeting and e-voting processes. Remote e-voting will be available from July 19, 2026, at 9:00 a.m. IST to July 21, 2026, at 5:00 p.m. IST, with a cut-off date of July 17, 2026, for determining eligibility.

Key AGM and Dividend Details

The notice also includes resolutions for the appointment of M/s. S.R. Batliboi & Associates LLP as Statutory Auditors for a term of five years, remuneration for Independent Directors, and the approval of remuneration for specified related party employees. Additionally, shareholders will vote on an Upside Sharing Arrangement with Viridity Tone LLP. The company noted that dividends are taxable in the hands of shareholders, and Tax Deducted at Source (TDS) will be applicable as per prescribed rates.

Anthem Biosciences has voluntarily filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, aligning with its commitment to responsible business practices and enhanced stakeholder disclosures. The filing, submitted to BSE Limited and the National Stock Exchange of India, precedes the regulatory requirement which becomes applicable from FY 2026-27. The report outlines the company's ESG initiatives, including the establishment of an ESG and Climate Change Committee at the Board level to oversee sustainability-related risks and opportunities.

The company’s operations are primarily driven by contract research, development, and manufacturing services, which accounted for 100% of its turnover. Exports contributed significantly to the business, constituting 85% of the revenue from operations for FY 2026. Anthem Biosciences operates three manufacturing plants nationally and serves 25 states within India, alongside a presence in 50 international markets. The customer base includes mid-sized and large biotechnology companies seeking end-to-end support in drug discovery and commercialization.

Environmental and Operational Initiatives

Anthem Biosciences has implemented several measures to mitigate environmental impact, including the adoption of Zero Liquid Discharge (ZLD) systems across all three manufacturing locations. The company procures renewable energy through solar and wind-based power purchase agreements and has transitioned boiler fuel from furnace oil to PNG to reduce emissions. Waste management practices include the disposal of hazardous waste through authorized recyclers and the achievement of Extended Producer Responsibility (EPR) targets for plastic waste.

The company reported total Scope 1 emissions of 17,596.37 metric tonnes of CO2 equivalent and Scope 2 emissions of 2,338.52 metric tonnes of CO2 equivalent for FY 2025-26. An independent assurance statement on the identified sustainability information was provided by Vinay and Keshava LLP, confirming the data's adherence to BRSR Core criteria.

Social and Governance Metrics

The company employed 2,282 permanent employees and 1,020 other than permanent workers as of the end of the financial year. Women comprised 12.50% of the Board of Directors and 20% of Key Management Personnel. Anthem Biosciences maintained a zero Lost Time Injury Frequency Rate (LTIFR) across both employees and workers and conducted regular safety audits. The company reported no instances of fines, penalties, or legal actions involving its Directors or Key Managerial Personnel during the reporting period.

Financial and CSR Disclosures

As per the Ind AS standalone financial statements, the company recorded a turnover of ₹20,893.12 million and a net worth of ₹30,768.08 million. Corporate Social Responsibility (CSR) initiatives focused on technology incubation, education, healthcare, and environmental sustainability, with projects such as the Anthem Academy and plantation drives in Harohalli. The spending on well-being measures for employees and workers was 0.16% of total revenue for FY 2025-26.